WO1999058121A1 - Novel fatty analogues for the treatment of obesity, hypertension and fatty liver - Google Patents
Novel fatty analogues for the treatment of obesity, hypertension and fatty liver Download PDFInfo
- Publication number
- WO1999058121A1 WO1999058121A1 PCT/NO1999/000135 NO9900135W WO9958121A1 WO 1999058121 A1 WO1999058121 A1 WO 1999058121A1 NO 9900135 W NO9900135 W NO 9900135W WO 9958121 A1 WO9958121 A1 WO 9958121A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- accordance
- coor
- integer
- animal
- fatty acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to novel fatty acid analogous which can be used for the treatment and/or prevention of obesity, fatty liver and hypertension. Further, the invention relates to a nutritional composition comprising such fatty acid analogues, and a method for reducing the total weight, or the amount of adipose tissue in an animal. The invention also relates to a method for improving the quality of product such as meat, milk and eggs.
- Hyperlipidemia and obesity afflict an increasing proportion of the population in Western societies and are associated with the development of serious conditions such as atherosclerosis, hypertension, fatty liver and insulin resistance. These conditions may eventually lead to the clinical manifestations of coronary heart diseases (CD) and non-insulin dependent diabetes mellitus (NIDDM) .
- CD coronary heart diseases
- NIDDM non-insulin dependent diabetes mellitus
- Treatment with modified fatty acids represent a new way to treat these diseases.
- EP 345.038 describes the use of non- ⁇ -oxidizable fatty acid analogues for the treatment of hyperlipidaemic conditions and for reducing the concentration of cholesterol and triglycerides in the blood of mammals.
- PCT/NO95/00195 describes alkyl-S-CH2COOR and alkyl-Se- CH2COOR for the inhibition of the oxidative modification OF ldl.
- fatty acid analogues are potent antidiabetic compounds, with a profound effect on the levels of glucose and insulin.
- the compounds have been proved to have an favourable effect on restenosis, and exhibit good anti- oxidative properties.
- Obesity is a chronic disease that is highly prevalent in modern society and is associated not only with a social stigma, but also with decreased life span and numerous medical problems, including adverse psychological development, reproductive disorders such as polycystic ovarian disease, dermatological disorders such as infections, varicose veins, Acanthosis nigricans, and eczema, exercise intolerance, diabetes mellitus, insulin resistance, hypertension, hypercholesterolemia, cholelithiasis, osteoarthritis, orthopedic injury, thromboembolic disease, cancer, and coronary heart disease.
- Existing therapies for obesity include standard diets and exercise, very low calorie diets, behavioral therapy, pharmacotherapy involving appetite suppressants, thermogenic drugs, food absorption inhibitors, mechanical devices such as jaw wiring, waist cords and balloons, and surgery.
- Caloric restriction as a treatment for obesity causes catabolism of body protein stores and produces negative nitrogen balance.
- the obesity herein may be due to any cause, whether genetic or environmental.
- disorders that may result in obesity or be the cause of obesity include overeating and bulimia, polycystic ovarian disease, craniopharyngioma, the Prader-Willi Syndrome, Frohlich's syndrome, Type II diabetics, GH-deficient subjects, normal variant short stature, Turner's syndrome, and other pathological conditions showing reduced metabolic activity.
- Increased blood pressure is a common condition in the developed countries of the world where, in very broad terms, the population eat too much and do not take sufficient exercise.
- Hypertension can have a variety of uncomfortable and dangerous side effects and it is seen as a major risk factor in relation to coronary heart disease. Hypertension can be associated with specific causes such as kidney disease or adrenal tumours but in most instances it is not. Obesity is regarded as a risk factor in relation to hypertension and a first line strategy in relation to obese hypertensive patients is to suggest weight reduction. It is therefore reasonable to anticipate that the present compounds, e.g. TTA and TSA which can have an effect on obesity, will reduce hypertension.
- the mechanism of production of fatty hepatosis is not entirely clear, but appears to be a combinaticn of several factors, such as sparing action of ethanol oxidation on utilization of liver triacylglycerols, excessive mobilization of triacylglycerols from adipose tissue to the liver caused in part by action of ethanol in triggering release of hormones, and failure to synthesize sufficient lipoprotein for transport of triacylglycerols because of alterations of amino acid availability.
- Fatty cirrhosis is characterized by the liver cells being infiltrated with fat (triacylglycerols) .
- the infiltration usually being due to alcohol ingestion.
- Fatty liver as a concomitant of the ingestion of high fat diets, alcohols or chlorinated hydrocarbons is a well-known phenomenon.
- Chronic intake of ethanol results in, among other things, hepatic injury to the accumulation of tri- glycerides and eventually, cirrhosis.
- the compounds of the present invention both activates the ⁇ -oxidation, and also reduces the concentration of triglycerieds in the liver.
- TTA Tetradecylthioacetic acid
- TTA has properties very similar to natural fatty acids, the main difference being that TTA is not oxidised by the mitochondrial ⁇ -oxidation system.
- the presence of compounds of the present invention have been shown to increase the ⁇ -oxidation of other (non-substituted fatty acids).
- the compound of the present invention modifies the composition of the lipids in various tissues. It is also shown that the present compounds modifies the fat content, and it is anticipated that the present compounds also will modify the fat distribution.
- TTA and TSA are far more potent in this respect than polyunsaturated fatty acids like EPA.
- TTA is a potent ligand of PPAR ⁇ , a transcription factor regulating the catabolism of fatty acids and eicosanoids, and a less potent ligand of PPAR ⁇ , which is involved in the regulation of adipocyte differentiation.
- NIDDM non insulin dependent diabetes mellitus
- a risk factor for its development is often linked to hypertension, dyslipidemia, elevated levels of plasma free fatty acids and an increased risk of cardiovascular disease.
- NIDDM patients are characterised by resistance to insulin action on glucose uptake in peripheral tissues and dysregulated insulin secretion.
- TTA decrease hyperinsulinemia and markedly improved insulin action on glucose utilisation. TTA did also prevent diet-induced insulin resistance. In contrast to the prior known antidiabetic glitazones TTA did not increase body weight gain.
- the compounds of the present invention inhibit an increase in the body weight and adipose tissue mass of animals given either a high fat or a high sucrose diet.
- the compounds of the present invention can be used as an anti-diabetic drug by reducing the concentration of glucose in the blood.
- the compounds of the present invention reduce the plasma concentration of insulin in hyperinsulineamic animals.
- the compounds of the present invention have been shown to strengthen the effect of endogenous insulin.
- metabolic syndrome is used to describe a multimetabolic syndrome which is inter alia characterised by hyperinsulinemia, insulin resistance, obesity, glucose intolerance, Type 2 diabetes mellitus, dyslipidemia or hypertension .
- the compounds of the present invention have been shown to provide a positive effect on all the conditions mentioned above, i.e. by regulating both the glucose and lipid homeostasis, and thus it is anticipated that the compounds of the present invention will be suitable agents for the regulation of the above defined metabolic disease (sometimes called syndrome X) .
- modified fatty acid analogues at non-cytotoxic concentrations can be used for the treatment and/or prevention of obesity, hypertension and fatty liver.
- the present invention relates to the use of fatty acid analogues of the general formula (I) :
- i is an odd number and indicates the position relative to COOR
- X ⁇ independent of each other are selected from the group comprising 0, S, SO, SO2, Se and CH2, and
- R represents hydrogen or C-L-C4 alkyl
- the invention relates to the use of a compound of the general formula I wherein m > 13. That is a compound which contains at least 14 carbons on the co side of the X group.
- Tetradecylthioacetic acid TTA
- Tetradecylselenioacetic acid TSA
- the present invention relates to the use of a compound of the formula I for the preparation of a pharmaceutical composition for the treatment and/or prevention of hypertension.
- a further aspect of the invention relates to the use of a compound of the formula I for the preparation of a pharmaceutical composition for the treatment and/or prevention of fatty liver.
- Still a further aspect of the invention relates to the use a compound of the formula I for the preparation of a pharmaceutical composition for the treatment and/or prevention of the multi metabolic syndrome termed «metabolic syndrome» which is inter alia characterised by hyperinsulinemia, insulin resistance, obesity, glucose intolerance, Type 2 diabetes mellitus, dyslipidemia and/or hypertension.
- metabolic syndrome is inter alia characterised by hyperinsulinemia, insulin resistance, obesity, glucose intolerance, Type 2 diabetes mellitus, dyslipidemia and/or hypertension.
- novel fatty acid analogues We have also synthesised and characterised novel fatty acid analogues, and thus in accordance with the present invention there is provided novel compounds of the formula I:
- n is an integer from 1 to 12
- i is an odd number and indicates the position relative to COOR
- X ⁇ independent of each other are selected from the group comprising 0, S, SO, SO2, Se and CH2, and
- R represents hydrogen or C- ⁇ -C ⁇ alkyl, - with the proviso that at least one of the X ⁇ is not CH 2 .
- a further aspect of the invention relates to a method for the treatment or prevention of an obese or overweight condition, said method comprising the step of administering to an animal in need thereof an effective amount of fatty acid analogues of the general formula (I) :
- n is an integer from 1 to 12
- i is an odd number and indicates the position relative to COOR
- X ⁇ independent of each other are selected from the group comprising 0, S, SO, SO2, Se and CH2, and
- R represents hydrogen or C- ⁇ -C ⁇ alkyl
- said animal is a human.
- said animal is an agricultural animal, such as gallinaceous birds, bovine, ovine, caprine or porcine mammals .
- said animal is a domestic or pet animal, such as dog or cat.
- said animal is a fish or shellfish, such as salmon, cod, Tilapia, clams, oysters, lobster or crabs.
- the treatment involves administering to a patient in need of such treatment a therapeutically effective concentration which is maintained substantially continuously in the blood of the animal for the duration of the period of its administration .
- the invention relates to a pharmaceutical composition for the prevention and/or treatment of obesity, hypertension or fatty liver.
- the pharmaceutical composition comprises in admixture with the fatty acid analogues a pharmaceutically acceptable carrier or excipient .
- the invention also relates to a nutritional composition
- a nutritional composition comprising an amount of fatty acid analogues of the general formula (I) effective to reduce, or to prevent an increase in, the total body weight or the total body fat mass in a human or non-human animal, and a method for producing weigh loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto an effective amount of a composition comprising fatty acid analogues of the general formula (I) .
- Preferred embodiments relate to a conditions wherein the animal has developed an obese condition or is low energy adapted. Still another embodiment of the invention relates to the modification of the fat distribution, concentration and content of animals in order to improve the quality of the meat, visually, nutritionally and customer acceptability or product such as milk and eggs.
- Preferred embodiments include agricultural animals, such as gallinaceous birds, bovine, ovine, caprine or porcine mammals, or fish or shellfish, such as salmon, cod, Tilapia, clams, oysters, lobster or crabs.
- agricultural animals such as gallinaceous birds, bovine, ovine, caprine or porcine mammals, or fish or shellfish, such as salmon, cod, Tilapia, clams, oysters, lobster or crabs.
- Figure 1 shows the effect of TTA on weight gain for rats given a high fat diet.
- Figure 2 shows the effect of TTA on weight gain for rats given a high sucrose diet.
- FIG. 3 shows that TTA treatment prevents high fat diet induced hyperinsulinemia.
- FIG. 4 shows that TTA treatment prevents high fat diet induced insulin resistance.
- FIG. 5 shows that TTA treatment reduces blood insulin and glucose concentrations in 5 week old Zucker (fa/fa) rats.
- FIG 6 shows that TTA treatment reduces blood insulin and glucose concentrations in 4 month old Zucker (fa/fa) rats ( Figure 5B.
- FIG. 7 shows that TTA treatment decreases the plasma insulin response to glucose.
- FIG. 8 shows that TTA increases the mitochondrial ⁇ - oxidation.
- Obesity normally refers to a condition whereby an animal has a Body Mass Index (BMI) which is above 25,9.
- BMI Body Mass Index
- the term «obesity» has a broader interpretation, i.e. indicating a condition wherein the BMI is above a desired value (above normal and below BMI) .
- the term obesity also covers the medical definition «simple obesity» which is a condition resulting when the caloric intake exceeds energy expenditure .
- low energy adapted refers to a condition whereby an animal has a low energy consumption, i.e. less then normal .
- mammals include mammals such as humans and farm (agricultural) animals, especially the animals of economic importance such as gallinaceous birds, bovine, ovine caprine and porcine mammals, especially those that produce products suitable for the human consumption, such as meat, eggs and milk, such as.
- the term is intended to include fish and shellfish, such as salmon, cod, Tilapia, clams and oysters.
- the term also includes domestic animals such as dogs and cats.
- treatment refers to a reduction of the severity of the disease, e.g. by reducing the total body weight or by reducing the fat mass.
- prevention refers to preventing obesity from occurring, i.e. a compound of the present invention is administered prior to the onset of the obese condition.
- the compounds of the present invention can be used as prophylactic agents to inhibit weight gain, or to impede an increase in body fat mass .
- the compounds of the present invention may be administered directly to the animal by any suitable technique, including parenterally, intranasally, orally, or by absorption through the skin. They can be administered locally or systemically .
- the specific route of administration of each agent will depend, e.g., on the medical history of the animal.
- parenteral administration examples include subcutaneous, intramuscular, intravenous, intraarterial, and intraperitoneal administration
- the total pharmaceutically effective amount of each of the compounds administered parenterally per dose will preferably be in the range of about 5 mg/kg/day to 1000 mg/kg/day of patient body weight, although, as noted above, this will be subject to a great deal of therapeutic discretion.
- a dose of 100 - 500 mg/kg/day is preferable, and for TSA the dosage could probably in the range of from 10 to 100 mg/kg/day.
- the compounds of the present invention are each typically administered by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump.
- An intravenous bag solution may also be employed.
- the key factor in selecting an appropriate dose is the result obtained, as measured by decreases in total body weight or ratio of fat to lean mass, or by other criteria for measuring control or prevention of obesity or prevention of obesity-related conditions, as are deemed appropriate by the practitioner.
- the compounds of the present invention are formulated generally by mixing each at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- a pharmaceutically acceptable carrier i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- the formulations are prepared by contacting the compounds of the present invention each uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation.
- the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes .
- the carrier may suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability.
- additives such as substances that enhance isotonicity and chemical stability.
- Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or non-ionic surfactants such as polysorbates, poloxamers, or PEG.
- buffers such as phosphate, citrate
- compositions such carrier material as, for example, water, gelatine, gums, lactose, starches, magnesium-stearate, talc, oils, polyalkene glycol, petroleum jelly and the like may be used.
- Such pharmaceutical preparation may be in unit dosage form and may additionally contain other therapeutically valuable substances or conventional pharmaceutical adjuvants such as preservatives, stabilising agents, emulsifiers, buffers and the like.
- the pharmaceutical preparations may be in conventional liquid forms such as tablets, capsules, dragees, ampoules and the like, in conventional dosage forms, such as dry ampulles, and as suppositories and the like.
- the treatment with the present compounds may occur without, or may be imposed with, a dietary restriction such as a limit in daily food or calorie intake, as is desired for the individual patient.
- the compounds of the present invention are appropriately administered in combination with other treatments for combatting or preventing obesity.
- the obese Zucker (fa/fa) rats used in this study were bred at the U 465 INSERM animal facility from pairs originally provided by the Harriet G. Bird Laboratory (Stow, MA, USA) . Unless otherwise stated, the animals were maintained under a constant light-dark cycle (light from 7:00 a.m. to 7:00 p.m.) at 21+1 C° and were given free access to food and water. Three rats were housed per cage. Weight gains were recorded daily.
- mice Male Wistar Charles River rats weighing 280-358 were purchased from AnLab Ltd. (Prague, Czech Repubic) and housed in wire-mesh cages in a temperature (22 ⁇ 1 °C) and light-controlled (light from 7.00 a.m. to 7.00 p.m.) room. They were given free access to chow and water. Three rats were housed per cage. Weight gain and food intake were recorded daily.
- Rats were fed a Standard Laboratory Rat Chow STl from Velaz, Prague, Czech Republic.
- High sucrose diet (HS)
- HS + TTA Same as HS + 0,3 % TTA dissolved in the beef tallow.
- HS + fish oil (FO) Beef tallow and sunflower oil is replaced by 10% Triomar. Triomar is from Pronova Biocare, Norway and contains 33,4 % EPA, 3,1% DPA and 20,2% DHA.
- High fat (HF) 1,9% gelatin, 5,7% wheat bran, 7,7% vitamins and minerals, 25,4% corn starch, 25,7% casein, 26,8% beef tallow and 7,1 % sunflower oil.
- HF + TTA Same + 0,4% TTA dissolved in the beef tallow.
- HF + FO 10% beef tallow is replaced by 10% Triomar.
- Intravenous glucose tolerance tests Male Zucker (fa/fa) rats (5 weeks old) were anaesthetised after a 5-hours fast, by intraperitoneal injection of sodium pentobarbital (50 mg/kg) . The rats were injected with glucose (0.55 g/kg) in the saphenous vein and blood samples were collected from the tail vein in heparinized tubes at time 0, 5, 10, 15, 20 and 30 minutes after the glucose load. Samples were kept on ice, centrifuged and plasma was stored at -20 °C until analysis.
- Hyperinsulinemic euglycemic clamp After 21 days on their respective diets (see above) , the rats were anaesthetised by injection of xylazine hydrochloride (Rometar SPOFA, Prague, Czech Republic; 10 mg/ml) and ketamine hydrochloride (Narkamon SPOFA, Prague, Czech republic; 75 mg/ml) , and fitted with chronic carotid artery and jugular vein cannulas as described by Koopmans et al. (Koopmans, S.J., et al., Biochim Biophys Acta, 1115, 2130- 2138 1992.).
- the cannulated rats were allowed to recover for two days after surgery before the clamping studies which were carried out according to Kraegen et al. (Kraegen, E. W. , et al., Am J Physiol, 248, E353-E362
- Glucose GLU, Boehringer Mannheim, Germany
- free fatty acids NEFA, C ACS-ACOD kit; Wako Chemicals, Dalton, USA
- b-hydroxybutyrate 310-A kit; Sigma Diagnostics Inc., St. Louis, USA
- Insulin concentrations were determined with radioimmunoassay by (CIS bio International, Gif sur Yvette, France) using rat insulin as standard in the Zucker rats.
- CIS bio International Gif sur Yvette, France
- plasma glucose concentrations were measured with the aid of Beckman Glucose Analyzer (Fullerton, CA, USA) .
- Plasma insulin levels were measured using a RIA kit from Linco Research Inc. (St. Charles, MO, USA).
- Phospholipids were measured by the enzymatic method of bioMerieux, Marcy-1 "Etoile, France, Triacylglycerol by the Technicon Method no. SA4-0324L90, USA and Cholesterol by the Technicon Method no. SA4- 0305L90, USA.
- Acid soluble products were measured in post-nuclear and mitochondrial enriched fractions, using [1- 14 C]- palmitoyl-CoA and [1- 14 C] -palmitoyl-L-carnitine (Radio- chemical Centre, Amersham, England) as substrates as described earlier (Willumsen, N., et al . , J. Lipid Res., 34, 13-22 1993.
- Carnitine palmitoyltransferase-I and -II activities were measured in the post-nuclear and mitochondrial fractions essentially as described by Bremer (Bremer, J. , Biochim. Biophys.
- RNA expression was estimated as the amounts of radioactive probe hybridised to the respective levels of 28S rRNA.
- Alkyl-Hal was replaced by Alcanoic-Hal and HS-CHCOOR was replaced by alkyl-SH.
- X is a sulphur atom
- the thio-substituted compound used according to the present invention may be prepared by the general procedure indicated below:
- TTA tetradecylthioaceticacid
- X is a selenium atom: the seleno-substituted compound used according to the present invention may be prepared by the following general procedure
- This compound was purified by carefully crystallisation from ethanol or methanol.
- Alkyl-Se-Se-Alkyl 2 Alkyl-Se ⁇
- the final compound e.g. when alkyl is tetradecyl, (CH3- (CH2) 13 -Se-CH2-COOH (tetradecylselinioacetic acid (TSA) ) can be purified by crystallisation from diethyl ether and hexane.
- TSA tetradecylselinioacetic acid
- the dose level of 500 mg/kg/day also elicited body weight loss. There was no evidence of toxicity at dose levels of 50 or 500 mg/day/kg.
- TTA and TSA did not induce mutations in strains of Salmonella typhimurium and Escherichia coli. Furthermore, TTA was not mutagenic when tested in mouse lymphoma cells and L5178Y.
- TTA concentration of the compounds tested in S . typhimurium and E. coli 3-1000 mg/plate (TTA) 2-5000 mg/plate (TSA) .
- TSA concentration of the compounds tested in mouse lymphoma cells, L5178Y
- the concentration was 2,5 - 50 mg/ml.
- TSA and TSA were found not to be mutagenic in these tests.
- TSA and TTA have been tested for chromosomal aberrations in cultured Chinese hamster ovary cells and no aberrations were induced by the doses tested (12-140 mg/ml) .
- the compounds of the present invention are therefore potentially useful as pharmaceutical compounds in this respect .
- mice Male obese Zucker fa/fa rats, weighing 100 g at the start of the experiment, were housed in pairs in metal wire cages in a room maintained at 12 h light-dark cycles and a constant temperature of 20+3 °C. The animals were acclimatised for at least one week under these conditions before the start of the experiment.
- TTA tetradecylthioacetic acid prepared in accordance with procedure described previously, and palmitic acid (control), was suspended in 0.5% (w/v) carboxymethyl cellu- lose (CMC) . Six animals were used in both groups.
- TTA decreases the levels of triglycerides, cholesterol and phospholipid in the plasma.
- TTA and TSA induce a lipid lowering effect in normal animals (Wistar rats)
- mice Male Wistar rats, weighing 180-200 g at the start of the experiment, were housed individually in metal wire cages in a room maintained at 12 h light-dark cycles and a constant temperature of 20 ⁇ 3 °C. The animals were acclimatised for one week under these conditions before the start of the experiments .
- TTA, TSA and eicosapentaenoic acid were suspended in 0,5% (w/v) carboxymethyl cellulose (CMC).
- CMC carboxymethyl cellulose
- Six animals were used for each treatment, and a 0,5% CMC solution was administrated to the rats as control. After administration of the test compound, the rats were fasted for 12 hours and anaesthetised with haloethan.
- the EPA and the fatty acid derivatives were administered by gastric intubation (gavage) once daily for 7 days. Blood samples were collected by cardiac puncture, and lipid concentrations in plasma were determined as outlined in the method section. The results are given in table 2 Table 2 Effect of TTA, TSA and EPA - on plasma lipid levels in rats .
- Table 2 shows that TTA exhibits a good lipid lowering effect in blood of rats. It will appear that a 100 times greater dose of the EPA is necessary to obtain the same decrease in the plasma lipid concentration as obtained for TSA. Moreover, the substituted fatty acid compounds of the present invention are much more effective than pure EPA and fish oil in lowering plasma lipids. Therefore they are potentially useful as medical compounds.
- mice Male Wistar Charles River rats (280-360 g) were fed 3 different diets (see methods) for 3 weeks ad libi tum . Afterwards, they were killed by decapitation, liver and epididymal adipose tissue pads were dissected out and weighed.
- TTA decreases the total body weight of normal rats
- Figure 1 shows the cumulated values for weight gain (g) /total food eaten (g) over 3 weeks. The values were calculated by taking the daily average weight gain and dividing it by the average amount of food eaten that day. See method section for the abbreviations and the specification of the diets.
- Example 8 The composition of the diets are given in the method section. Example 8.
- Figure 2 shows the cumulated values for weight gain (g) / total food eaten (g) over 3 weeks. The values were calculated by taking the daily average weight gain and dividing it by the average amount of food eaten that day. See method section for the abbreviations and the specification of the diets.
- composition of the diets are given in the method section.
- the TTA was also tested for its effect on liver and adipose tissue weight. The results are indicated in table 5.
- Example 10 TTA induces a weight reduction in dogs
- TTA treatment prevents HF diet induces hyperinsulinemia in normal rats
- FIG. 3 shows that the TTA treatment prevents high fat diet-induced hyperinsulinemia in Wistar Charles River rats.
- TTA treatment prevents HF diet induced insulin resistance in normal rats
- FIG. 4 shows that TTA treatment prevents high fat diet- induced insulin resistance in Wistar Charles River rats.
- the TTA treatment reduced the blood insulin concentration by almost 40%, whereas the blood concentration of glucose was reduced approximately by 15%.
- Figure 6 shows the effect on TTA on the levels of blood insulin and glucose in 4 month old Zucker (fa/fa) rats, i.e. rats which have developed hyperglycaemia (Sparks, J. D. et al, Metabolism, 47, 1315-1324 1998.),.
- TTA treatment decreases the plasma insulin response to glucose
- IVGTT intravenous glucose tolerance test
- the relative mRNA levels were determined by densiometric scanning of the autoradiograms and the different mRNA levels were normalised to the respective 28S rRNA and the means for the controls were set to 1. Formation of aci d soluble products in control obese animals was 1.3 ⁇ 0.7 and 5.312.2 nmol/g liver/min using palmitoyl-CoA and palmitoyl- L-carnitine as substrates respectively.
- the CPT-I activity in control rats were 22.14.9 nmol/g liver /min., and the CPT-II activity in control rats were 2701115 nmol/g liver/min. Values are expressed as the mean 1 S.D.
- TTA administration increased plasma concentrations of ketone bodies, resulting in a marked decrease in the FFA/ ketone body ratio (Table 7) .
- Table 7 The TTA administration increased plasma concentrations of ketone bodies, resulting in a marked decrease in the FFA/ ketone body ratio.
- TTA treatment of 4 month old obese Zucker (fa/fa) rats increased hepatic mitochondrial ⁇ -oxidation and keto- genesis.
- TTA treatment of obese Zucker (fa/fa) rats increased liver fatty acid oxidation more than 7-fold as measured with palmitoyl-CoA and palmitoyl-L-carnitine as substrates (Figure 8A) .
- This induction of b-oxidation was accompanied by an increase of activity and mRNA levels of both CPT-I ( Figure 8B) and CPT-II ( Figure 8C) .
- the activities of the rate-limiting enzymes in ketogenesis were increased (Table 7).
- Example 17 The effect of TTA on hepatic levels of triacylglycerol
- the significant increased mitochondrial fatty acid oxidation caused by TTA will reduce the availability of fatty acids for esterification.
- the synthesis of triacylglycerol and cholesterol is thus reduced, and the secretion of VLDL from the liver is decreased. This is reflected in a decreased level of triacylglycerol in the liver, reduced plasma triacylglycerol, and reduced adipose tissue mass. Basal and total lypolysis are not changed (data not shown) and the ratio between plasma free fatty acids and ketone bodies is decreased (data not shown) . This indicates an increased flux of fatty acids from the peripheral tissues to the liver for oxidation.
- TTA Tetradecyl-4-thia propionic acid
- TTP is a fatty acid analogue with a sulphur atom in the 4 position. This analogue inhibits the ⁇ -oxidation of fatty acids due to the formation of a mitochondrial inhibitor. Feeding rats with this analogue results in the formation of fatty. However, if the rats are fed with a combination of TTA and TTP, the formation of fatty liver is avoided (Table 8).
- TTA may be used for the treatment of conditions with an increased hepatic level of triacylglycerol.
- Male Wistar rats had free access to water and rat maintenance chow. They were fed palmitic acid or fatty acid analogues suspended in 0,5% CMC for 6 days. In some experiments TTA or TTP were fed for 3 days before feeding both for 6 days. At the end of the experiment the rats were fasted overnight, killed, the liver removed and homogenized. Triacylglycerol was measured in the homogenate .
- TTA 150 mg/kg/day
- TTP 300 mg/kg/day
- Example 18 Fatty acid analogues have been synthesised where the sulphur atom is moved to positions further from the carboxylic group of the fatty acid.
- these analogues will be partially ⁇ -oxidised.
- ⁇ -oxidation removes two C atoms at a time from the carboxylic end of the fatty acid, and such analogues may thus be ⁇ -oxidised until the sulphur atom is in the 3- position. It is thus conceivable that such analogues may have biological effects similar to TTA.
- fatty acid analogues related by having a sulphur atom in an odd numbered position on the carbon chain will all increase the mitochondrial ⁇ -oxidation (Table 9) .
- the mitochondrial ⁇ -oxidation is measured as in example 16 with the use of [1- 1 C] -palmitoyl-L-carnitine as substrates .
- Example 19 Male obese Zucker fa/fa rats, weighing 100 g at the start of the experiment, were housed in pairs in metal wire cages in a room maintained at 12 h light-dark cycles and a constant temperature of 2013 °C. The animals were acclimatised for at least one week under these conditions before the start of the experiment.
- TTA and palmitic acid were suspended in 0.5% (w/v) carboxymethyl cellulose (CMC) and administered at a dose of 300 mg/day/kg body weight, by gastric intubation (gavage) once daily for 10 days.
- CMC carboxymethyl cellulose
- the rats were fasted for 2 hours before termination of the experiment. Blood and organs were collected. Total lipids were extracted from liver and plasma. The lipids were evaporated, saponified and esterified prior to separation using a Carlo Erba 2900 gas-chromatograph. Table 10
- Table 10 shows that oral administration of TTA increases the level of oleic acid in both liver and plasma. Also a delta-9-desaturated product of TTA accumulated in both plasma and liver.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99933292A EP1075258B1 (en) | 1998-05-08 | 1999-04-23 | Novel fatty analogues for the treatment of obesity |
JP2000547972A JP5057003B2 (en) | 1998-05-08 | 1999-04-23 | Novel fatty analogues for the treatment of obesity, hypertension and fatty liver |
US09/700,061 US6441036B1 (en) | 1998-05-08 | 1999-04-23 | Fatty analogues for the treatment of obesity, hypertension and fatty liver |
BR9910296-0A BR9910296A (en) | 1998-05-08 | 1999-04-23 | New fatty analogs for the treatment of obesity, hypertension and fat in the liver |
CA002331408A CA2331408C (en) | 1998-05-08 | 1999-04-23 | Fatty analogues for the treatment of obesity, hypertension and fatty liver |
AT99933292T ATE247464T1 (en) | 1998-05-08 | 1999-04-23 | NEW FAT ANALOGUES TO TREAT OBESITY |
DE69910559T DE69910559T2 (en) | 1998-05-08 | 1999-04-23 | NEW FAT ANALOGS FOR THE TREATMENT OF OBESITY |
NZ508045A NZ508045A (en) | 1998-05-08 | 1999-04-23 | A nutritional composition comprising the fatty acid analogues and a method for reducing total weight or the amount of adipose tissue in animals |
AU49366/99A AU762792B2 (en) | 1998-05-08 | 1999-04-23 | Novel fatty analogues for the treatment of obesity, hypertension and fatty liver |
DK99933292T DK1075258T3 (en) | 1998-05-08 | 1999-04-23 | New fatty acid analogues for the treatment of obesity |
NO20005461A NO20005461L (en) | 1998-05-08 | 2000-10-30 | New fatty acid analogues for the treatment of obesity, hypertension and fatty liver |
HK01105690A HK1034912A1 (en) | 1998-05-08 | 2001-08-14 | Novel fatty analogues for the treatment of obesity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NOPCT/NO98/00143 | 1998-05-08 | ||
PCT/NO1998/000143 WO1999058120A1 (en) | 1998-05-08 | 1998-05-08 | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999058121A1 true WO1999058121A1 (en) | 1999-11-18 |
Family
ID=19907879
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NO1998/000143 WO1999058120A1 (en) | 1998-05-08 | 1998-05-08 | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
PCT/NO1999/000135 WO1999058121A1 (en) | 1998-05-08 | 1999-04-23 | Novel fatty analogues for the treatment of obesity, hypertension and fatty liver |
PCT/NO1999/000136 WO1999058122A1 (en) | 1998-05-08 | 1999-04-23 | Novel fatty analogues for the treatment of diabetes |
PCT/NO1999/000149 WO1999058123A2 (en) | 1998-05-08 | 1999-05-07 | Novel fatty acid analogues for the treatment of primary and secondary restenosis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NO1998/000143 WO1999058120A1 (en) | 1998-05-08 | 1998-05-08 | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NO1999/000136 WO1999058122A1 (en) | 1998-05-08 | 1999-04-23 | Novel fatty analogues for the treatment of diabetes |
PCT/NO1999/000149 WO1999058123A2 (en) | 1998-05-08 | 1999-05-07 | Novel fatty acid analogues for the treatment of primary and secondary restenosis |
Country Status (18)
Country | Link |
---|---|
US (4) | US6441036B1 (en) |
EP (5) | EP1285652B1 (en) |
JP (3) | JP2002514595A (en) |
KR (3) | KR100701502B1 (en) |
CN (3) | CN1245157C (en) |
AT (5) | ATE336239T1 (en) |
AU (4) | AU7240398A (en) |
BR (2) | BR9910297A (en) |
CA (3) | CA2331395C (en) |
DE (5) | DE69932645D1 (en) |
DK (3) | DK1075259T3 (en) |
ES (3) | ES2207253T3 (en) |
HK (3) | HK1034911A1 (en) |
NO (3) | NO333143B1 (en) |
NZ (3) | NZ508045A (en) |
PT (2) | PT1075259E (en) |
RU (3) | RU2219920C2 (en) |
WO (4) | WO1999058120A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021575A1 (en) * | 1999-09-17 | 2001-03-29 | Women's And Children's Hospital Adelaide | Anti-inflammatory nitro- and thia- fatty acids |
WO2001068582A1 (en) * | 2000-03-03 | 2001-09-20 | Thia Medica As | Novel fatty acid analogous |
WO2005073164A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
WO2006009465A2 (en) * | 2004-07-19 | 2006-01-26 | Thia Medica As | Composition comprising protein material and non-oxidizable fatty acid entities |
AU784588B2 (en) * | 1999-09-17 | 2006-05-04 | Peplin Biolipids Pty Ltd | Anti-inflammatory nitro- and thia- fatty acids |
US7504426B2 (en) | 2002-09-06 | 2009-03-17 | Janssen Pharmaceutica N.V. | Heterocyclic compounds |
KR100905335B1 (en) * | 2000-11-28 | 2009-07-01 | 티아 메디카 에이에스 | Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
US8178713B2 (en) | 2002-06-20 | 2012-05-15 | Pronovo Biopharma Norge AS | Sulfur-containing phospholipid derivatives |
WO2014140934A2 (en) | 2013-03-11 | 2014-09-18 | Life Science Nutrition As | Natural lipids containing non-oxidizable fatty acids |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058120A1 (en) * | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
WO2001037827A1 (en) * | 1999-10-13 | 2001-05-31 | Chacon Marco A | Therapeutic intervention to mimic the effect of caloric restriction |
NO20003591L (en) * | 2000-07-13 | 2002-01-14 | Thia Medica As | Fatty acid analogues for the treatment of cancer |
DE10115740A1 (en) * | 2001-03-26 | 2002-10-02 | Ulrich Speck | Preparation for restenosis prophylaxis |
IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
IL142536A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Carriers for therapeutic preparations for treatment of t-cell mediated diseases |
US6908632B1 (en) | 2002-04-19 | 2005-06-21 | Pharmanex, Llc | Blood glucose modulating compositions and methods |
DK1547614T3 (en) * | 2002-05-28 | 2011-04-04 | Ajinomoto Kk | Medical composition for inhibiting the expression of ATP citrate lyase and its use |
US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
US7045547B2 (en) * | 2002-08-20 | 2006-05-16 | University Of Delaware | Acyl-CoA dehydrogenase allenic inhibitors |
NZ539625A (en) * | 2002-09-27 | 2007-11-30 | Martek Biosciences Corp | Improved glycemic control for Prediabetes and/or Diabetes Type II Using Docosahexaenoic Acid |
ZA200502613B (en) * | 2002-10-10 | 2006-10-25 | Yeda Res & Dev | Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
FR2850650B1 (en) * | 2003-01-31 | 2005-03-25 | Genfit S A | THERAPEUTIC USE OF ACYLGLYCEROLS AND THEIR NITROGEN AND SULFUR ANALOGUES |
FR2850869B1 (en) * | 2003-02-12 | 2005-03-25 | Genfit S A | USES OF ACYLATED AMINOPROPANEDIOLS AND THEIR NITROGEN AND SULFUR ANALOGUES |
WO2004071458A2 (en) | 2003-02-13 | 2004-08-26 | Albert Einstein College Of Medicine Of Yeshiva University | REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS |
US20050215558A1 (en) * | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
US8137994B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
US8137993B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
CN1961213A (en) * | 2004-05-28 | 2007-05-09 | 詹森药业有限公司 | New intravenous drug administration and blood sampling model in the awake rat |
DE102004034640A1 (en) | 2004-07-16 | 2006-02-16 | Institut für Molekular- und Systemmedizin | Method for systemic biocorrection of an organism |
NO324534B1 (en) * | 2004-07-19 | 2007-11-19 | Thia Medica As | Material prepared from a combination of non-β-oxidizable fatty acid analogues and a plant oil or fish oil and uses thereof |
WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
US7288525B2 (en) * | 2004-12-28 | 2007-10-30 | The Research Foundation Of State University Of New York | Method for lowering serum homocysteine |
US20070026079A1 (en) * | 2005-02-14 | 2007-02-01 | Louis Herlands | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels |
EP1888727B1 (en) * | 2005-05-04 | 2015-04-15 | Pronova BioPharma Norge AS | New dha derivatives and their use as medicaments |
US7586003B2 (en) * | 2005-07-14 | 2009-09-08 | Zinpro Corporation | Derivatives of seleno-amino acids |
NO20053519L (en) * | 2005-07-18 | 2007-01-19 | Thia Medica As | Use of compounds comprising fatty acids |
NO20055541L (en) * | 2005-11-23 | 2007-05-24 | Berge Biomed As | Use of fatty acid analogues |
GB0605900D0 (en) * | 2006-03-23 | 2006-05-03 | Lipigen As | Modulators of nuclear receptors |
US20080085293A1 (en) * | 2006-08-22 | 2008-04-10 | Jenchen Yang | Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor |
BRPI0718420A2 (en) | 2006-10-20 | 2013-11-12 | Cpd Llc | RESEARCH METHOD OF INCRETIN EFFECT |
EP2129646A2 (en) * | 2006-11-01 | 2009-12-09 | Pronova Biopharma Norge AS | Omega-3 lipid compounds |
CA2667211A1 (en) * | 2006-11-01 | 2008-05-08 | Pronova Biopharma Norge As | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar) |
EP2114155A4 (en) * | 2007-02-26 | 2014-04-16 | Yeda Res & Dev | Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses |
US20080221115A1 (en) * | 2007-02-26 | 2008-09-11 | Liat Hayardeny-Nisimov | Use of long-chain alcohol derivatives for the treatment of alopecia areata |
ES2748136T3 (en) | 2007-10-15 | 2020-03-13 | United Animal Health Inc | Method to increase the performance of the young |
EP2217558A1 (en) * | 2007-10-31 | 2010-08-18 | Pronova Biopharma Norge AS | New dha derivatives and their use as medicaments |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
KR101225320B1 (en) * | 2008-04-29 | 2013-01-22 | 에프. 호프만-라 로슈 아게 | 4-trimethylammonio-butyrates as cpt2 inhibitors |
EP2147910A1 (en) * | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
AU2009293019A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care Inc. | Solute concentration measurement device and related methods |
CA2760877C (en) | 2009-05-08 | 2020-09-08 | Pronova Biopharma Norge As | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
AU2010278894B2 (en) | 2009-07-30 | 2014-01-30 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
BR112013003658B1 (en) | 2010-07-28 | 2022-02-22 | Life Technologies Corporation | Pharmaceutical composition comprising azide-modified isoprenoid fatty acid, carbohydrate and lipid, use of such components and method of inhibiting infectivity of a virus |
US20120028335A1 (en) | 2010-07-28 | 2012-02-02 | Life Technologies Corporation | Anti-viral azide-containing compounds |
KR102265409B1 (en) | 2010-11-05 | 2021-06-16 | 바스프 에이에스 | Methods of treatment using lipid compounds |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
EP2961384B1 (en) | 2013-02-28 | 2019-08-28 | Basf As | A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
US10154979B2 (en) | 2013-03-11 | 2018-12-18 | Sciadonics, Inc. | Lipid compositions containing bioactive fatty acids |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
RU2522224C1 (en) * | 2013-08-06 | 2014-07-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" | Method of treatment of acute hepatosis in cats |
CN107405343A (en) | 2014-11-07 | 2017-11-28 | 明尼苏达大学董事会 | Salt and composition available for treatment disease |
EP3288550A1 (en) | 2015-04-28 | 2018-03-07 | Pronova BioPharma Norge AS | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis |
US10492141B2 (en) | 2015-11-17 | 2019-11-26 | Tandem Diabetes Care, Inc. | Methods for reduction of battery usage in ambulatory infusion pumps |
KR20200075815A (en) * | 2017-10-23 | 2020-06-26 | 에피트래커, 인코포레이티드 | Fatty acid analogs and their use in the treatment of metabolic syndrome related conditions |
EP3720431A1 (en) | 2017-12-06 | 2020-10-14 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
EP3934639A4 (en) * | 2019-03-04 | 2023-01-11 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0345038A2 (en) * | 1988-06-02 | 1989-12-06 | Norsk Hydro A/S | Non-beta-oxidizable fatty acid analogues with the effect to reduce the concentration of cholesterol and triglycerides in blood of mammals |
WO1997003663A1 (en) * | 1995-07-14 | 1997-02-06 | Rolf Berge | NON-β-OXIDIZABLE FATTY ACID ANALOGUES, THEIR USES AS THERAPEUTIC ACTIVE MEDICAMENTS, AND PREPARATION THEREOF |
EP0843972A1 (en) * | 1996-11-20 | 1998-05-27 | N.V. Nutricia | Nutritional composition comprising fats for the treatment of the metabolic syndrome |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59175425A (en) * | 1983-03-25 | 1984-10-04 | Otsuka Pharmaceut Co Ltd | Vessel strengthening agent |
US6063581A (en) * | 1992-01-22 | 2000-05-16 | Axis-Shield Asa | Immunoassay for homocysteine |
WO1996040098A2 (en) * | 1995-06-07 | 1996-12-19 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
WO1999058120A1 (en) * | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
-
1998
- 1998-05-08 WO PCT/NO1998/000143 patent/WO1999058120A1/en active Application Filing
- 1998-05-08 AU AU72403/98A patent/AU7240398A/en not_active Abandoned
-
1999
- 1999-04-23 DK DK99933293T patent/DK1075259T3/en active
- 1999-04-23 CN CNB998059668A patent/CN1245157C/en not_active Expired - Fee Related
- 1999-04-23 DE DE69932645T patent/DE69932645D1/en not_active Expired - Lifetime
- 1999-04-23 US US09/700,061 patent/US6441036B1/en not_active Expired - Lifetime
- 1999-04-23 AT AT02024616T patent/ATE336239T1/en not_active IP Right Cessation
- 1999-04-23 DK DK99933292T patent/DK1075258T3/en active
- 1999-04-23 ES ES99933292T patent/ES2207253T3/en not_active Expired - Lifetime
- 1999-04-23 AT AT99933293T patent/ATE245416T1/en not_active IP Right Cessation
- 1999-04-23 RU RU2000131222/15A patent/RU2219920C2/en not_active IP Right Cessation
- 1999-04-23 EP EP02024616A patent/EP1285652B1/en not_active Expired - Lifetime
- 1999-04-23 KR KR1020007012281A patent/KR100701502B1/en not_active IP Right Cessation
- 1999-04-23 AT AT02024388T patent/ATE334666T1/en not_active IP Right Cessation
- 1999-04-23 CA CA002331395A patent/CA2331395C/en not_active Expired - Fee Related
- 1999-04-23 EP EP02024388A patent/EP1284139B1/en not_active Expired - Lifetime
- 1999-04-23 CN CNB998059684A patent/CN1223343C/en not_active Expired - Fee Related
- 1999-04-23 CA CA002331408A patent/CA2331408C/en not_active Expired - Fee Related
- 1999-04-23 BR BR9910297-8A patent/BR9910297A/en not_active Application Discontinuation
- 1999-04-23 WO PCT/NO1999/000135 patent/WO1999058121A1/en active IP Right Grant
- 1999-04-23 ES ES99933293T patent/ES2204142T3/en not_active Expired - Lifetime
- 1999-04-23 RU RU2000131221/14A patent/RU2221558C2/en not_active IP Right Cessation
- 1999-04-23 EP EP99933293A patent/EP1075259B1/en not_active Expired - Lifetime
- 1999-04-23 BR BR9910296-0A patent/BR9910296A/en not_active IP Right Cessation
- 1999-04-23 KR KR1020007012282A patent/KR100701503B1/en not_active IP Right Cessation
- 1999-04-23 DE DE69932864T patent/DE69932864D1/en not_active Expired - Lifetime
- 1999-04-23 PT PT99933293T patent/PT1075259E/en unknown
- 1999-04-23 DE DE69910559T patent/DE69910559T2/en not_active Expired - Lifetime
- 1999-04-23 PT PT99933292T patent/PT1075258E/en unknown
- 1999-04-23 US US09/700,062 patent/US6365628B1/en not_active Expired - Lifetime
- 1999-04-23 JP JP2000547973A patent/JP2002514595A/en active Pending
- 1999-04-23 EP EP99933292A patent/EP1075258B1/en not_active Expired - Lifetime
- 1999-04-23 AU AU49366/99A patent/AU762792B2/en not_active Ceased
- 1999-04-23 NZ NZ508045A patent/NZ508045A/en not_active IP Right Cessation
- 1999-04-23 JP JP2000547972A patent/JP5057003B2/en not_active Expired - Fee Related
- 1999-04-23 DE DE69909775T patent/DE69909775T2/en not_active Expired - Lifetime
- 1999-04-23 AT AT99933292T patent/ATE247464T1/en not_active IP Right Cessation
- 1999-04-23 WO PCT/NO1999/000136 patent/WO1999058122A1/en active IP Right Grant
- 1999-04-23 AU AU49367/99A patent/AU762790B2/en not_active Ceased
- 1999-04-23 NZ NZ508047A patent/NZ508047A/en not_active IP Right Cessation
- 1999-05-07 AU AU54517/99A patent/AU761355B2/en not_active Ceased
- 1999-05-07 DE DE69927805T patent/DE69927805T2/en not_active Expired - Fee Related
- 1999-05-07 AT AT99940723T patent/ATE306916T1/en not_active IP Right Cessation
- 1999-05-07 US US09/674,982 patent/US6417232B1/en not_active Expired - Lifetime
- 1999-05-07 DK DK99940723T patent/DK1075260T3/en active
- 1999-05-07 ES ES99940723T patent/ES2251218T3/en not_active Expired - Lifetime
- 1999-05-07 WO PCT/NO1999/000149 patent/WO1999058123A2/en active IP Right Grant
- 1999-05-07 RU RU2000131220/15A patent/RU2223095C2/en not_active IP Right Cessation
- 1999-05-07 KR KR1020007012283A patent/KR100822077B1/en not_active IP Right Cessation
- 1999-05-07 CN CNB998059676A patent/CN1244323C/en not_active Expired - Fee Related
- 1999-05-07 JP JP2000547974A patent/JP4465672B2/en not_active Expired - Fee Related
- 1999-05-07 CA CA002331393A patent/CA2331393C/en not_active Expired - Fee Related
- 1999-05-07 NZ NZ508046A patent/NZ508046A/en not_active IP Right Cessation
- 1999-05-07 EP EP99940723A patent/EP1075260B1/en not_active Expired - Lifetime
-
2000
- 2000-10-30 NO NO20005462A patent/NO333143B1/en not_active IP Right Cessation
- 2000-10-30 NO NO20005463A patent/NO20005463L/en not_active Application Discontinuation
- 2000-10-30 NO NO20005461A patent/NO20005461L/en not_active Application Discontinuation
-
2001
- 2001-08-14 HK HK01105689A patent/HK1034911A1/en not_active IP Right Cessation
- 2001-08-14 HK HK01105684A patent/HK1034909A1/en not_active IP Right Cessation
- 2001-08-14 HK HK01105690A patent/HK1034912A1/en not_active IP Right Cessation
-
2002
- 2002-05-17 US US10/151,203 patent/US7026356B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0345038A2 (en) * | 1988-06-02 | 1989-12-06 | Norsk Hydro A/S | Non-beta-oxidizable fatty acid analogues with the effect to reduce the concentration of cholesterol and triglycerides in blood of mammals |
WO1997003663A1 (en) * | 1995-07-14 | 1997-02-06 | Rolf Berge | NON-β-OXIDIZABLE FATTY ACID ANALOGUES, THEIR USES AS THERAPEUTIC ACTIVE MEDICAMENTS, AND PREPARATION THEREOF |
EP0843972A1 (en) * | 1996-11-20 | 1998-05-27 | N.V. Nutricia | Nutritional composition comprising fats for the treatment of the metabolic syndrome |
Non-Patent Citations (1)
Title |
---|
DATABASE STN CAPLUS 1 January 1900 (1900-01-01), XP002919880, Database accession no. 1997:308235 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU784588B2 (en) * | 1999-09-17 | 2006-05-04 | Peplin Biolipids Pty Ltd | Anti-inflammatory nitro- and thia- fatty acids |
WO2001021575A1 (en) * | 1999-09-17 | 2001-03-29 | Women's And Children's Hospital Adelaide | Anti-inflammatory nitro- and thia- fatty acids |
WO2001068582A1 (en) * | 2000-03-03 | 2001-09-20 | Thia Medica As | Novel fatty acid analogous |
JP2003527364A (en) * | 2000-03-03 | 2003-09-16 | ティア、メディカ、アクチスカベット | New fatty acid analogs |
US7902399B2 (en) | 2000-03-03 | 2011-03-08 | Thia Medica As | Fatty acids analogous |
KR100905335B1 (en) * | 2000-11-28 | 2009-07-01 | 티아 메디카 에이에스 | Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
US8178713B2 (en) | 2002-06-20 | 2012-05-15 | Pronovo Biopharma Norge AS | Sulfur-containing phospholipid derivatives |
US7504426B2 (en) | 2002-09-06 | 2009-03-17 | Janssen Pharmaceutica N.V. | Heterocyclic compounds |
WO2005073164A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
WO2006009465A3 (en) * | 2004-07-19 | 2006-09-14 | Thia Medica As | Composition comprising protein material and non-oxidizable fatty acid entities |
WO2006009464A3 (en) * | 2004-07-19 | 2006-08-24 | Thia Medica As | Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
US7659242B2 (en) | 2004-07-19 | 2010-02-09 | Thia Medica As | Composition comprising protein material and compounds comprising non-oxidizable fatty acid entities |
AU2005264782B2 (en) * | 2004-07-19 | 2010-12-16 | Thia Medica As | Composition comprising protein material and non-oxidizable fatty acid entities |
WO2006009464A2 (en) * | 2004-07-19 | 2006-01-26 | Thia Medica As | Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
AU2005264781B2 (en) * | 2004-07-19 | 2011-07-28 | Life Science Nutrition As | Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
WO2006009465A2 (en) * | 2004-07-19 | 2006-01-26 | Thia Medica As | Composition comprising protein material and non-oxidizable fatty acid entities |
EP2275140A3 (en) * | 2004-07-19 | 2012-08-08 | Thia Medica AS | Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
WO2014140934A2 (en) | 2013-03-11 | 2014-09-18 | Life Science Nutrition As | Natural lipids containing non-oxidizable fatty acids |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2331408C (en) | Fatty analogues for the treatment of obesity, hypertension and fatty liver | |
Maljaars et al. | Ileal brake: a sensible food target for appetite control. A review | |
EP2275140B1 (en) | Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities | |
WO2005060954A1 (en) | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof | |
US7834058B2 (en) | Method of using catalpic acid to treat hyperinsulinemia | |
MXPA00010998A (en) | Novel fatty analogues for the treatment of diabetes | |
Cawthorne et al. | The search for peripherally acting drugs for the treatment of obesity-a review | |
JP2004505041A (en) | Methods and compositions for the prevention and treatment of Syndrome X |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99805968.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2331408 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007012281 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 508045 Country of ref document: NZ Ref document number: IN/PCT/2000/622/CHE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999933292 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 49366/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09700061 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999933292 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007012281 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999933292 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 49366/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007012281 Country of ref document: KR |